Pheochromocytoma-paraganglioma
MONDO:0035540A rare neuroendocrine tumor arising from chromaffin cells of the adrenal medulla (pheochromocytoma) or from sympathetic and parasympathetic ganglia (paraganglioma). These tumors are most often benign and may produce catecholamines in excess causing hypertension and sometimes severe acute cardiovascular complications.
1451 clinical trials for this condition and its sub-types, 18 tagged with Pheochromocytoma-paraganglioma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New pill shows promise for rare tumors in Mid-Stage trial
Disease control Recruiting nowThis phase 2 study tests belzutifan, a daily pill that blocks a protein called HIF-2α, in people with advanced rare cancers like pheochromocytoma/paraganglioma, pancreatic neuroendocrine tumors, VHL disease-associated tumors, and certain other solid tumors. The goal is to see if …
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New radiation drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a radioactive drug that seeks out and delivers radiation directly to cancer cells with a specific protein (somatostatin receptor). It is for adults with advanced lung, kidney, head and neck, digestive tract, or adrenal gland tumors that cannot be remo…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New radioactive drug targets Hard-to-Treat gut and adrenal tumors
Disease control Recruiting nowThis study tests a new radioactive drug, [212Pb]VMT-alpha-NET, in people with advanced gastrointestinal neuroendocrine tumors or pheochromocytoma/paragangliomas that have already been treated with radiation therapy. The drug is designed to attach to a protein on the surface of th…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New hope for rare adrenal cancer: drug trial launches
Disease control Recruiting nowThis phase 2 trial is testing a drug called ONC206 in 90 people with advanced pheochromocytoma or paraganglioma, rare tumors of the adrenal glands. Participants must have tumors that cannot be removed by surgery and have not responded to or cannot have standard treatments. The st…
Phase 2 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Promising combo targets Hard-to-Treat childhood cancers
Disease control Recruiting nowThis study is testing a combination of two drugs—a targeted radioactive drug (177Lu-DOTATATE) and a PARP inhibitor (olaparib)—in children and teens aged 3 to 18 with certain solid tumors that have come back or not responded to treatment. The goal is to see if the combination is s…
Phase 1/2 • Sponsor: Fundación de investigación HM • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for VHL patients: belzutifan trial targets rare tumor disorder
Disease control Recruiting nowThis study tests the drug belzutifan in 100 people with von Hippel-Lindau (VHL) syndrome, a genetic condition that causes tumors in various organs. Researchers will track how well the drug shrinks tumors and how long it takes for the disease to progress, while also monitoring sid…
Phase 2 • Sponsor: José Claudio Casali da Rocha • Aim: Disease control
Last updated Jun 26, 2026 15:43 UTC
-
New scan could spot hidden cancers better than current methods
Diagnosis Recruiting nowThis study tests whether a new imaging agent called [18F]FAPI-74 can find certain cancers as well as or better than the standard PET tracer. About 320 adults with one of 11 cancer types (including pancreatic, liver, ovarian, and lung cancers) will receive both tracers and have th…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Jun 27, 2026 12:35 UTC
-
New scan could spot rare tumors better than current gold standard
Diagnosis Recruiting nowThis study tests a newer type of PET/CT scan (Al18F-NOTA-LM3) against the current standard (68Ga-DOTATATE) to see which finds more tumors in people with pheochromocytoma or paraganglioma (PPGL). About 40 adults with suspected or confirmed PPGL will receive both scans, and doctors…
Sponsor: Peking Union Medical College Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 08:04 UTC
-
Could a cancer drug quiet overactive adrenal hormones? a new study investigates.
Knowledge-focused Recruiting nowThis pilot study looks at how belzutifan, a drug already used for some tumors, changes the production of adrenaline-like hormones in people with pheochromocytoma and paraganglioma (PPGL). Over 5 days, researchers measure key substances in the hormone-making process to see if belz…
Phase 2 • Sponsor: Cambridge University Hospitals NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Hunt for hidden cancer genes: families needed to unlock hereditary secrets
Knowledge-focused Recruiting nowThis study aims to discover new genes that may cause certain cancers to run in families. Researchers will collect blood samples and health information from 1,500 people in families where multiple members have had cancer, especially childhood cancers. The goal is to build a regist…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC